AmerisourceBergen Drug Corp. v. CuraScript Inc.

83 Pa. D. & C.4th 362, 2007 Phila. Ct. Com. Pl. LEXIS 116
CourtPennsylvania Court of Common Pleas, Philadelphia County
DecidedApril 17, 2007
Docketno. 2272
StatusPublished

This text of 83 Pa. D. & C.4th 362 (AmerisourceBergen Drug Corp. v. CuraScript Inc.) is published on Counsel Stack Legal Research, covering Pennsylvania Court of Common Pleas, Philadelphia County primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
AmerisourceBergen Drug Corp. v. CuraScript Inc., 83 Pa. D. & C.4th 362, 2007 Phila. Ct. Com. Pl. LEXIS 116 (Pa. Super. Ct. 2007).

Opinion

ABRAMSON, J,

The focus of this appeal is whether a deposition may be reopened and a deponent questioned as to his private off-the-record conversation with counsel after he changed his testimony.

On February 19,2007, counsel for CuraScript Inc. and Priority Health Care Corporation (CuraScript) deposed Alan Clock, former vice president of Alternative Care at AmerisourceBergen. Mr. Clock was allegedly involved in negotiations of an agreement between the parties [364]*364herein. During his deposition, CuraScript’s counsel questioned Mr. Clock regarding his understanding of the liquidated damages provision contained within the CuraScript agreement. In response, Mr. Clock testified that the provision would serve to compensate AmerisourceBergen for any damages incurred in the past, present and future as it related to the deal. During a CuraScript counsel’s question, three breaks occurred. Once CuraScript’s counsel completed his questioning, AmerisourceBergen’s counsel’s first question to the deponent was as follows:

“By Mr. Garcia:

“Q. Mr. — Mr. Clock I would just like to clarify a couple of points regarding your testimony. I think in one area you may have misspoken. Would you turn to exhibit LaBrecque 4 please?”

In response, Mr. Clock testified as follows:

“Q. And specifically the second terminated the contract is the termination amount specified in paragraph 7?

“A. No.

“Q. Uhm, by no do you mean that’s not your understanding?

“A. That’s not my understanding. That this would be the only, uhm — that this would be the only damages if, uhm, CuraScript terminated the contract.

“Q. If you look at the second sentence under paragraph 7 where it says in the last clause, ‘in addition to any other amounts that may be owned [sic] to AmerisourceBergen, as of the termination date,’ did you have an understanding of what types of other additional amounts that might be referring to?

[365]*365“A. It — it could be a varieties of things. It could be, uhm, past due invoice, late fees. I mean it could be a variety of things that are — in the — in this agreement and including the — you know any other things as it relates to, uhm — anything else in this — this agreement.

“Q. Well, for example, if CuraScript did not comply with the 3.5 percent ProGenrics requirement—

“Mr. Monafo: Objection. Leading.

“Mr. Garcia: Let me finish the question yet, how do you know.

“Mr. Monafo: You already led him, I already violated the rules so the objection is valid. You go right ahead and finish your leading question.

“Q. For example if CuraScript violated the 3.5 percent requirement, is that something that you would interpret to be within the type of items that AmeriSource could recover for notwithstanding this termination payment?

“By Mr. Monafo: Objection. Leading.

“Mr. Garcia: It’s yes-or-no question.

“Mr. Monafo: It’s also a leading yes-or-no question.

“The witness: I — presume that — that that would be something that they, uhm — that AmerisourceBergen would be able to — to recover as well, as I read this.

“Q: Do you understand this provision to be precluding recovery of profits lost into the future after the termination?

“A. I — I don’t know if it says that or not in this, one way or the other. I mean I’m not a legal expert.

[366]*366“Q. So in your opinion or do you have an opinion one way or the other as to whether or not AmeriSource would be entitled to recover lost profits for the income it wouldn’t have received during the rest of the term because of the termination?

“Mr. Monafo: Objection. Asked and answered. He already answered it, but go ahead.

“The witness: I don’t really have an opinion one way or the other.

“Mr. Garcia: Okay. That’s all I have, that clarifies it. Thank you.” (Cite)

This testimony was different than that testimony rendered in response to questions posed by CuraScript’s counsel. After AmerisourseBergen’s counsel completed his questioning, CuraScript’s counsel questioned Mr. Clock as follows:

“Mr. Monafo: Thank you. I have a question now based on that clarification.

“Examination

“Mr. Monafo:

“Q. Uhm, Mr. Clock, uhm, at any time during the breaks of this deposition, did you discuss this provision Mr. Garcia just asked you about, any other amounts that may be owed?

“Mr. Garcia:

“Objection to any discussions. That would be privileged attorney/client communications.

“Mr. Monafo: Okay. Are you instructing him not to answer?

“Mr. Garcia: Of course.

[367]*367. “Mr. Monafo: Are you accepting your counsel’s advice?

“The witness: Yes. (Direction not to answer.)

“Q. We did take breaks in the — throughout the deposition, did we not?

“A. Yes.

“Q. And you had a chance to visit with your counsel during those breaks?

“Mr. Monafo: Rudy, I think if you — if you discussed it after I asked him about it in the — in the — during the duration of the deposition that it’s not — it’s not covered by the privilege. That would be my position.

“Mr. Garcia: Well, I will — you’re free to state your position. I don’t agree with it, but it doesn’t matter. Any conversations we had are covered by the privilege.” (Deposition of Mr. Clock pp. 208-16.)

CuraScript filed a discovery motion specifically addressing whether the meaning of the liquidated damage provision was discussed during the private off-the-record conversation between counsel for AmerisourceBergen and Mr. Clock. On March 13, 2007, this court entered an order granting a motion to compel the reopening of a deposition to respond to questions regarding the witness’s private conversations with counsel for AmerisourceBergen after the start of, but prior to, the completion of the deposition. This appeal followed. AmerisourceBergen also filed an emergency motion to suspend the case pending appeal. The court denied the motion and stated, “The court also instructed, and the attorneys understood, that [368]*368that which was to be disclosed were conversations which might have caused the witness to change, modify or alter testimony on a subject already discussed, not all privileged communications.” CuraScript filed an emergency application for stay or suspension pending appeal with the Superior Court which was granted.

“Generally, on review of an order concerning discovery, an appellate court applies an abuse of discretion standard.”1 To the extent that the question involves a pure issue of law, the scope and standard of review are plenary.2

Our analysis begins with Hall v. Clifton Precision, 150 F.R.D. 525 (E.D. Pa. 1993), an opinion by Federal District Judge Robert S. Gawthrop III, which established specific rules of conduct for counsel at a discovery deposition due to discovery abuses he found to commonly occur within his district.3

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Prudential Insurance Co. of America v. Nelson
11 F. Supp. 2d 572 (D. New Jersey, 1998)
McNeil v. Jordan
894 A.2d 1260 (Supreme Court of Pennsylvania, 2006)
Yoskowitz v. Yazdanfar
900 A.2d 900 (Superior Court of Pennsylvania, 2006)
McKinley Infuser, Inc. v. Zdeb
200 F.R.D. 648 (D. Colorado, 2001)
Plaisted v. Geisinger Medical Center
210 F.R.D. 527 (M.D. Pennsylvania, 2002)
United States v. Philip Morris Inc.
212 F.R.D. 418 (District of Columbia, 2002)
Hall v. Clifton Precision
150 F.R.D. 525 (E.D. Pennsylvania, 1993)
Johnson v. Wayne Manor Apartments
152 F.R.D. 56 (E.D. Pennsylvania, 1993)
O'Brien v. Amtrak
163 F.R.D. 232 (E.D. Pennsylvania, 1995)
Damaj v. Farmers Insurance
164 F.R.D. 559 (N.D. Oklahoma, 1995)
In re Stratosphere Corp. Securities Litigation
182 F.R.D. 614 (D. Nevada, 1998)

Cite This Page — Counsel Stack

Bluebook (online)
83 Pa. D. & C.4th 362, 2007 Phila. Ct. Com. Pl. LEXIS 116, Counsel Stack Legal Research, https://law.counselstack.com/opinion/amerisourcebergen-drug-corp-v-curascript-inc-pactcomplphilad-2007.